Upstream Bio (NASDAQ:UPB – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.
Analyst Recommendations
This is a summary of recent ratings for Upstream Bio and Celularity, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
Upstream Bio presently has a consensus target price of $29.67, suggesting a potential upside of 775.12%. Given Upstream Bio’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Upstream Bio is more favorable than Celularity.
Profitability
This table compares Upstream Bio and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
| Celularity | -246.65% | N/A | -48.20% |
Institutional and Insider Ownership
19.0% of Celularity shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Upstream Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
Earnings and Valuation
This table compares Upstream Bio and Celularity”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Upstream Bio | $2.85 million | 65.15 | -$143.44 million | ($2.90) | -1.17 |
| Celularity | $26.55 million | 1.00 | -$91.72 million | ($1.69) | -0.48 |
Celularity has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.
Summary
Celularity beats Upstream Bio on 7 of the 13 factors compared between the two stocks.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
